For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

Aspire 13 adds official, first-class Python support so distributed apps can orchestrate Python services natively alongside ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...